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Abstract 
Increasing evidence suggests that vascular risk factors contribute to neurodegeneration, 
cognitive impairment and dementia. While there is considerable overlap between features of 
vascular cognitive impairment and dementia (VCID) and Alzheimer’s disease (AD), it 
appears that cerebral hypoperfusion is the common underlying pathophysiological 
mechanism which is a major contributor to cognitive decline and degenerative processes 
leading to dementia. Sustained cerebral hypoperfusion is suggested to be the cause of white 
matter attenuation, a key feature common to both AD and dementia associated with cerebral 
small vessel disease. White matter changes increase the risk for stroke, dementia and 
disability. A major gap has been the lack of mechanistic insights in the evolution and 
progress of VCID. However, this gap is closing with the recent refinement of rodent models 
which replicate chronic cerebral hypoperfusion. In this review, we discuss the relevance and 
advantages of these models to elucidating the pathogenesis of VCID and explore the 
interplay been hypoperfusion and the deposition of amyloid β protein, as it relates to AD. We 
use examples of our recent investigations to illustrate the utility of the model in pre-clinical 
testing of candidate drugs and life-style factors. We propose that the use of such models is 
necessary for tackling the urgently needed translational gap from preclinical models  to 
clinical  treatments .  
 
 
Key words: Alzheimer’s disease; animal models; cerebral hypoperfusion; cognitive 
impairment; dementia; small vessel disease; stroke; vascular dementia 
 
 
 
 
Summary statement:  
Vascular cognitive impairment and dementia (VCID) is an important contributor to the global 
burden of disease. While there are no perfect animal models to recapitulate all the features 
of VCID, current laboratory rodent models which simulate cerebral hypoperfusion allow 
some aspects of VCID to be explored. Despite their limitations, rodent models are still useful 
to evaluate specific mechanisms for testing drug targets and close the translational gap 
between animal models and VCID.  
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Introduction 
Vascular disease has been invariably linked to cognitive impairment. There is increasing 
evidence that vascular risk factors contribute to neurodegeneration and dementia. Recent 
analysis on a large sample, as part of the Alzheimer’s Disease Neuroimaging Initiative, 
surprisingly revealed that early vascular dysfunction plays a role in Alzheimer’s disease (AD) 
(1). However, one of the most common causes of vascular cognitive impairment and 
dementia (VCID) is cerebral small vessel disease (SVD), which affects small arteries, 
arterioles, venules and capillaries in the brain leading to arteriolar occlusion, lacunes and 
white matter changes. The main clinical features of VCID may include pure motor, 
sensorimotor, pure sensory, ataxic hemiparesis or gait impairment, dysarthria, cognitive 
dysexecutive slowing and depression (2). Cerebral amyloid angiopathy (CAA), another form 
of SVD, is found in almost all AD patients and more than 50% of the elderly over 90 years 
old (2, 3). CAA mostly leads to lobar haemorrhage, white matter damage and cortical 
microinfarcts (4). Moderate to severe CAA is also considered an independent risk factor for 
dementia (5).   
 
It is now recognised that there is considerable overlap between VCID and AD. Several 
previous reports, including recent ones from the AD research centres in the USA, suggest 
that some form of brain vascular pathology exists in up to 80% of sporadic late onset AD (6). 
Moreover, cerebrovascular lesions increase the clinical expression of AD syndrome. 
Traditional risk factors for stroke and cardiovascular disease (e.g. hypertension, diabetes, 
hyperlipidaemia) are recognised as risks for both VCID and AD with salt intake, chronic 
inflammation and gut infection now emerging as additional risk factors (7,8). Although the 
mechanisms by which these different factors may impact on VCID and AD are currently ill 
defined, considerable evidence, including that derived from neuroimaging and pathology 
studies, indicates that endothelial dysfunction is pivotal to the pathophysiology (see reviews 
9, 10, 11). It is proposed that risk factors may alter vascular haemodynamics and impact on 
endothelial cell function. Endothelial dysfunction can in turn reduce vasomotor reactivity and 
impede cerebral hemodynamic changes. Related to this vascular factors may impair 
neurovascular coupling, leading to transient or chronic cerebral hypoperfusion which 
exacerbates small vessel pathology including white matter damage. Alternatively, it is 
proposed that the blood brain barrier (BBB) is initially compromised in VCID leading to a 
chronic hypoxic state and hypoperfusion (see reviews 9, 10, 11).  
 
Cerebral hypoperfusion is emerging as a major contributor to cognitive decline and 
degenerative processes leading to dementia. Reduced cerebral perfusion correlates with the 
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severity of dementia and also predicts which individuals with mild cognitive impairment (MCI) 
will progress to develop dementia (12, 13). Cross-sectional studies show that low cerebral 
blood flow (CBF) is related to the severity of white matter hyperintensities upon T2 weighted 
MRI (14-16). Neuropathological investigations have revealed marked reductions in myelin 
density in the white matter in AD but particularly in VaD compared to age-matched controls 
(17-19) with evidence that this may be related to reduced white matter perfusion (20, 21). It 
is unclear whether CBF changes are causal or secondary to white matter changes. 
Nonetheless, imaging studies suggest the extent and presence of these white matter 
changes, particularly in the frontal lobe are important determinants of cognitive function and 
impact on dementia (22, 23). Thus it is proposed that understanding the earliest events 
leading to white matter changes could provide vital opportunities to prevent brain damage at 
the earliest stages and ameliorate its impact on cognitive decline and precipitation of 
dementia (23). 
 
In addition to correlative pathological and imaging studies in human, there is a need to 
provide mechanistic insight of white matter changes through the development of relevant 
animal models and translate these findings to the clinic (24). Over the past five decades, 
various animal models have been described to examine the pathophysiology of global and 
focal ischaemic injury (25, 26) (Figure 1). Several of these models were developed to 
primarily test the acute effects of compounds administered within the therapeutic window, 
after occlusion, to reduce the effects of focal stroke injury and salvage the hypoperfused 
region or penumbra peripheral to the ischaemic core (25). Several models have since been  
developed to mimic specific aspects of the pathology relevant to VCID or genetic causes 
(most recently reviewed in 27). In this current review, we focus on rodent models which have 
been developed and refined over the last few years to mimic the chronic hypoperfusive state 
in VCID and which are used as a basis to probe mechanisms related to reduced perfusion of 
the brain. We have focussed on models of bilateral common carotid artery occlusion in rats 
(often referred to as 2 vessel occlusion), bilateral common carotid artery stenosis (BCAS) 
model in mice and the newly developed bilateral common carotid artery gradual occlusion 
model in rats and mice. We also explore the interplay between cerebral hypoperfusion and 
amyloid beta protein (Aβ), which is currently being evaluated as a model in which to explore 
mixed dementia.  Finally, we discuss approaches currently underway to close the 
translational gap between the rodent models of cerebral hypoperfusion and human VCID.  
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What have we learned from the rodent models of chronic cerebral hypoperfusion? 
Cerebral blood flow alterations in models 
In order to study early pathological events that may lead to VCID, rodent models of chronic 
cerebral hypoperfusion were first established using occlusion or ligation of both common 
carotid arteries in rats (2 vessel occlusion) (see review 28). The resulting reductions in blood 
flow are severe, whereby cortical blood flow drops by over 70% in the days immediately 
following surgery, recovering to a 40% reduction by one month (29). In C57Bl/6J mice, 
complete occlusion of both carotid arteries leads to death due to poor collateral flow through 
the Circle of Willis and as an alternative the carotid arteries are temporarily occluded for 
durations lasting no more than 30 minutes (30). This approach leads to transient global 
ischaemia with blood flow reduced by 80-90% (31, 32). As such, these occlusion models do 
not accurately recapitulate the more modest reductions in blood flow seen in chronic 
hypoperfusive conditions related to VCI where blood flow may only be reduced by ~20-30% 
(33-35).  
 
A refinement of rat models of cerebral hypoperfusion was introduced to more faithfully 
represent the subtle reductions in flow in VCI. Bilateral common carotid artery stenosis 
(BCAS), by application of microcoils, reduces luminal diameter to approximately 50% in 
young adult C57Bl/6J mice (36). This approach takes advantage of the poor Circle of Willis 
in C57Bl/6J mice and results in blood flow reductions of 30-40% immediately following 
surgery using microcoils of 0.18mm diameter (36, 37). With increasing time there is a 
recovery of blood flow in young mice to 15-20% baseline levels at 1 month when measured 
by laser Doppler ultrasound or laser speckle imaging (36, 37). These changes have been 
attributed to vascular remodelling in young mice (38) but as yet the effects in older (>1 year) 
mice remain unknown. Blood flow measures are normally conducted using laser speckle or 
Doppler flowmetry and constrained by limited depth of penetration and the restriction of 
these techniques to the cortical surface vasculature. Hattori et al. (39) performed arterial spin 
labelling MRI to measure blood flow in cortical and subcortical brain regions following BCAS 
in mice. From 1 day up to 14 days following surgery, blood flow was shown to be reduced to 
50% of baseline in both cortical and subcortical regions, however at 28 days blood flow had 
recovered to 70% of baseline. Boehm-Sturm et al. (40) also utilised arterial spin labelling to 
demonstrate global flow reductions of 50% at 24 hours following BCAS surgery, recovering 
to ~75% of baseline at 4 weeks. Despite the recovery of blood flow, these studies 
importantly highlight that hypoperfusion is not restricted to the cortical vasculature and 
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supports BCAS as a model for chronic cerebral hypoperfusion. Thus, the studies emphasise 
the utility of arterial spin labelling as a quantitative and non-invasive tool for assessing global 
and regional blood flow changes in models of hypoperfusion. 
 
A limitation of the BCAS model is the acute reduction in CBF that occurs on application of 
the microcoils (36). To overcome this a new gradual stenosis model was developed which 
uses ameroid constrictor devices applied on both common carotid arteries arteries in rats 
and mice (41, 42). These ameroid devices absorb extracellular fluid over time and as a result 
gradually expand to constrict the arteries resulting in a slower, more gradual onset of 
hypoperfusion. In rats, a maximum blood flow reduction of 30% is observed at 3 days 
following surgery followed by recovery of blood flow to 85% of baseline when assessed for 
28 days similar to levels reached in the 2 vessel occlusion rat model (41). In mice however, 
blood flow progressively reduces over 28 days, without recovery, to reach 70% of baseline 
levels after the application of the constrictor cuffs (42). The differing patterns of blood flow 
reductions between the microcoil induced stenosis and gradual stenosis were illustrated by 
Hattori et al. (42), in which BCAS mice were compared to those with ameroid constrictor 
devices applied to the common carotid arteries (Figure 2). A gradual reduction in CBF can 
clearly be seen in the gradual stenosis mice whereas an acute drop in CBF is detected in the 
BCAS mice. In another model an ameroid constrictor is applied to the right common carotid 
artery resulting in gradual occlusion of the vessel over 28 days, whereas placement of a 
microcoil to the left common carotid artery induces ∼50% arterial stenosis (43). To our 
knowledge, there are no published data available on blood flow reductions at longer time 
points (>1 month) in ameroid constrictor models, and whether these devices eventually go 
on to completely occlude the carotid arteries remains to be confirmed. 
 
Neuropathological changes 
Parenchymal alterations 
As indicated previously white matter alterations, a prominent feature of VCID, contribute to 
cognitive impairment and serve as a potential target to ameliorate the burden of dementia 
(23). Rat 2 vessel occlusion models have been extensively studied since they were first 
found to develop white matter rarefaction similar to that in humans (28). However, these 
pathological changes occur very quickly in conjunction with the severe and sudden drop in 
cerebral perfusion after occlusion (29). Furthermore, in the 2 vessel occlusion model 
ischemic neuronal damage may be present in the cerebral cortex and hippocampus 1-3 days 
and infarctions in the striatum at 7 days (29) albeit this can vary considerably between 
studies and groups (see review, 28). In parallel with white/grey matter pathology, microglia 
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markedly increase in number which can be detected from as early as 1 day after occlusion in 
the white matter and remain significantly elevated at 28 days (44). A prominent astrocytic 
response is also evident in this model but appears delayed compared to the other 
pathological changes (44).  
 
A refinement of these 2 vessel occlusion rat models was undertaken to overcome the severe 
reduction in blood flow with the development of the BCAS microcoil models in mice. 
Investigation of this model led to the discovery that white matter is damaged in the absence 
of overt ischaemic neuronal perikaryal damage. Shibata et al. (36) using the BCAS model in 
mice first reported white matter rarefaction and vacuolation (detected using Klüver-Barrera), 
which is evident from 2 weeks alongside a prominent glial response that evolves with time. 
Others, including our group, have shown that BCAS using microcoils causes an anatomically 
widespread but diffuse damage to myelinated axons in white matter tracts detectable at one 
month (36, 45-47). These changes can be observed throughout the forebrain (such as 
corpus callosum, fimbria, internal capsule, optic tract) and can be visualised using 
immunohistochemical approaches in the form of degraded myelin basic protein and myelin 
debris with less pronounced axonal damage. Hypoperfusion also leads to selective 
disruption of key proteins within the paranodal axon-glial junctions, which are critical to the 
stability and functions of myelinated axons and white matter function (46). Paranodal 
septate-like junctions are damaged and axon-glial integrity is disrupted, as determined by 
spatial distribution of myelin-associated glycoprotein staining (46). Ultrastructural alterations 
comprise loss of septate junctions at paranodal regions (46) but that there is no overt 
demyelination in the model (37). Such subtle white matter pathology in the absence of 
severe focal disruption can be detected by diffusion tensor (DT) or magnetization transfer 
(MT) MRI first in the corpus callosum at one month (47), that then progresses over 6 months 
with more pronounced alterations in the corpus callosum, internal capsule, fimbria and 
subcortex (48). One of the prominent features of hypoperfusion models is a robust increase 
in microglial number. In response to increasing durations of hypoperfusion, microglia 
gradually augment in parallel with the evolving damage to myelinated axons, resulting in a 
marked and sustained increase in microglial number, particularly in the white matter (36, 37, 
45-47). Astrogliosis can also be observed but these changes appear to occur later than 
microglial alterations in BCAS models with diffuse white matter injury (48). However, in 
severely damaged white matter GFAP-positive clasmatodendrocytes (irreversibly damaged 
astrocytes) can be readily detected (40, 49).  
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Pathological changes in the gradual stenosis models are similar to the microcoil model but 
as expected these progress more slowly. In the rat gradual stenosis model, acute 
inflammatory responses subsequent to acute CBF reduction observed in the 2 vessel 
occlusion rats are eliminated (50). Myelin pathology (assessed by Klüver-Barrera, degraded 
MBP and GST-pi staining), is less severe in the gradual compared to the 2 vessel occlusion 
model, and disruption of axon-glial integrity is apparent at 28 days (50). Selective white 
matter changes are induced with relatively preserved neurovascular coupling and 
substantially less metabolic and histological derangements in the grey matter including the 
hippocampus in the gradual compared to 2 vessel occlusion model (50). Moreover, in the 
mouse gradual stenosis model, activation of astrocytes and microglia with loss of 
oligodendrocytes were found in the white matter at 32 days post-operation (39).  
 
Most of the mild hypoperfusion models do not exhibit overt white matter lesions or infarcts. 
However, using histological approaches and T2* MRI, after long-term BCAS subcortical 
microinfarcts and haemorrhages were evident (48). As yet the longer-term effects (>1 
month) have not been studied in the gradual stenosis models. 
 
Small vessel and BBB changes  
In the rat 2 vessel occlusion model, BBB disruption is observed as early as 3 hours post-
occlusion most likely as a result of the sharp and severe CBF reduction in this model (51). 
However as CBF restores from day 7, the BBB changes appear less prominent (51). In the 
BCAS model, it is not clear if the BBB is compromised but this could be explained by 
variations in CBF reductions across different models. In our BCAS model, overt BBB 
disruption was not observed until 6 months after hypoperfusion when fibrinogen was 
detected in the parenchyma and the levels of the tight junction protein claudin-5 were 
markedly reduced (48). Other studies, in which white matter damage appears more severe, 
showed earlier BBB disruption at 3 and 7 days after BCAS (52). An ultrastructural study 
suggested that subtle alterations in the BBB occur early whereby at two hours post BCAS, 
irregularities in the endothelium include opening of tight junctions (53). A systematic study of 
the BBB, including tight junction proteins, across a range of times post-hypoperfusion in the 
different models is required to assess the dynamics of the BBB and whether these changes 
may be transient or sustained.  
 
Sustained hypoperfusion can also induce morphological small vessel changes such as 
increased thickening and fibrosis of capillary walls, which are one of the characteristic 
features of human SVD (2). These features have been identified after 12 weeks 
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hypoperfusion in a rat 2 vessel occlusion model (28) and after 6 months hypoperfusion in a 
mouse BCAS model (48). Fibrin deposition or accumulation of hyaline-like substance, key 
neuropathological findings in human SVD, are also recognized after 6 months hypoperfusion 
in the BCAS mice (48). In the gradual stenosis models, small vessel and BBB changes are 
yet to be described.  
 
Brain atrophy  
Clinical imaging studies have demonstrated both whole brain and regional brain atrophy in 
VCID (54, 55). Brain atrophy, in particular medial temporal lobe atrophy and subcortical 
atrophy, is associated with cognitive decline and can potentiate the effect of white matter 
lesions on cognition (54, 56). Longitudinal progression of brain atrophy and white matter 
lesions are strongly correlated, with white matter lesions recently suggested to drive cortical 
grey matter atrophy (57). Despite the prevalence of brain atrophy in VCID and its relation 
with cognition, there is a relative paucity of evidence regarding brain atrophy in preclinical 
models of cerebral hypoperfusion. Nishio et al. (58) reported no apparent change in cortex or 
corpus callosum at 8 months following BCAS surgery, however the hippocampal volume was 
found to be significantly reduced in hypoperfused mice. In agreement with this finding, 
hippocampal glucose uptake was also reduced when assessed with 18F-FDG PET. Holland 
et al. (48) showed reductions in brain volume at 6 months following BCAS but not at 1 month 
using T2*MRI, atrophy was also correlated with burden of ischaemic and haemorrhagic 
lesions. Together, these findings suggest that brain atrophy occurs at later time points 
following hypoperfusion, and are secondary to neuronal loss and white matter damage. 
Future studies may utilise preclinical in vivo imaging where possible, in order to measure 
volumetric changes longitudinally over the entire volume of the brain, so as to definitively 
describe the pattern of atrophy following hypoperfusion. White matter alterations have been 
suggested to contribute to cortical atrophy (57) and thus the use of larger animal models with 
greater volume of white matter, for example non-human primates, may enable better 
understanding of this mechanism. Since brain atrophy is the major substrate of cognitive 
decline, atrophic change may be a useful endpoint when incorporated into preclinical 
intervention studies. 
 
Cognitive impairments 
It was proposed many years ago that chronic cerebral hypoperfusion leads to cognitive 
impairment (59) but human studies have shown at best a moderate association. Animal 
models have since provided compelling evidence that chronic cerebral hypoperfusion can 
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lead to cognitive impairments (see 28, 60, 61 for reviews). Most studies have utilised the 
Morris water maze to assess spatial reference learning or the radial arm maze tasks to 
assess spatial working memory. Impaired spatial learning has been widely reported in the 2 
vessel occlusion rat model (28, 60, 61) and in some studies deficits have been detected as 
early as 7 days post-occlusion (62). These behavioural changes reflect pathological changes 
in the hippocampus with proliferation of astrocytes and neuronal cell loss in the CA1 area 
(62, 63). At later time points impaired spatial working memory (28, 60) has been observed 
and correlates well with the development of white matter pathology. Interestingly, poor 
performance in the odour discrimination task suggests that cognitive functions related to 
olfaction are also impaired (64), which is also seen as an early sign of cognitive impairment 
in patients with various neurodegenerative diseases, indicating the relevance of this model 
to human VCID.  
The development of the BCAS mouse model demonstrated that chronic cerebral 
hypoperfusion causes deficits mainly in spatial working memory (45, 65-67) using a 
conventional 8-arm radial maze or Y-maze tests. We highlighted that 1 month after BCAS, 
spatial working memory is impaired while reference memory remains intact, probably due to 
the select disruption of frontal-subcortical circuits (45). Notably, disruption of axon-glial 
integrity and proliferation of microglia are indicated to be strongly associated with the 
impairment in working memory (68). Recent reports also confirm that BCAS causes impaired 
working memory assessed by an innovative three dimensional 9-arm radial maze as well as 
impaired nesting ability at four months after surgery (69). After long-term i.e. 6 months of 
hypoperfusion after BCAS, both spatial working memory and spatial reference memory were 
impaired (48). The emergence of deficits in both working and reference memory likely 
reflects the presence of white and grey matter pathology including whole brain and 
hippocampal atrophy (48, 70). Thus, long-term hypoperfusion induces a pronounced 
cognitive impairment coincident with pathological alterations and more accurately replicates 
features of human SVD. In the gradual stenosis mouse model, impaired spatial working 
memory is again reflective of white matter pathology whereas hippocampal-dependent 
reference learning and memory is preserved, probably due to a lack of hippocampal 
changes compared with other mouse models (42). Similarly, in the rat gradual occlusion 
model spatial working memory is impaired (41). In general, impaired spatial working memory 
is a consistent and robust finding in models of chronic cerebral hypoperfusion. This 
highlights the relevance of these models to human VCID in which the frontal-subcortical 
circuits are disrupted. 
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Mechanisms of the hypoperfusion models 
As indicated above, rodent models of hypoperfusion recapitulate some pathological features 
observed in VCID, such as disruption of white matter integrity, microvascular alterations and 
atrophy. These alterations are related to cognitive deficits. However, the precise molecular 
and cellular mechanisms that lead to such changes are currently being unravelled as 
outlined below: 
 
Hypoxia-induced white matter damage 
Following vessel occlusion or carotid stenosis, cerebral perfusion is demonstrably reduced 
(28, 37) but it is less clear whether these changes affect tissue oxygen tension and whether 
there are differences between white matter and grey matter to account for their differential 
vulnerability. Tissue levels of oxygen (pO2), can be measured using precalibrated sensors. 
We have used this approach to measure pO2 levels in the corpus callosum of anaesthetised 
mice in the BCAS model. Levels of pO2 are profoundly decreased in the corpus callosum at 
3 days, 1 week and 6 weeks following BCAS surgery (see Figure 3) to levels consistent with 
hypoxic conditions. The levels of pO2 in normal appearing white matter are less than those 
reported within grey matter (71) and may suggest that white matter is predisposed to 
additional reduction in oxygen caused by BCAS. Dong et al. (72) also reported an increase 
in hypoxia at 3 weeks following BCAS surgery, although regional differences were not 
assessed.  
At 3 days following hypoperfusion surgery in the BCAS model, we demonstrated expression 
of hypoxia-related genes in the white matter (46). Oligodendrocytes are sensitive to hypoxia 
(73, 74) and a rapid loss of oligodendrocytes occurs in the different models of hypoperfusion. 
At 3 days post-BCAS we demonstrated there is a loss of mature oligodendrocytes and 
oligodendrocyte precursors at a time when axon-glial integrity is compromised (37). Early 
hypoxic signalling could result in degeneration of oligodendrocytes and a loss of axonal 
trophic support, resulting in mis-localisation of key axonal proteins (46) that may impair 
signal conduction. In human post-mortem brain, disruption of nodal proteins has also been 
reported in white matter adjacent to lacunar infarcts (75) and white matter lesions express 
characteristic markers of a hypoxic environment, including hypoxia inducible factor 1 (HIF-1), 
HIF-2 and matrix metalloproteinase (MMP)-7 (19).  
Hypoxia, in addition to deleterious effects on oligodendrocytes, can also directly induce 
changes in BBB permeability (76). Intriguingly, oligodendrocytes and oligodendrocyte 
precursor cells have also been demonstrated to modulate BBB function by altering tight 
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junction protein expression (77). In the mouse BCAS model oligodendrocyte precursors 
were shown to be responsible for BBB opening, via increase MMP and contribute to white 
matter damage in hypoperfusion models (52). Blood-brain barrier dysfunction is also 
observed in white matter hyperintensities and normally appearing white matter in SVD that is 
predictive of cognitive decline (78). Disruption of oligodendrocyte-endothelial signalling may 
also allow entry of toxic blood products into brain contributing to the pathophysiology of 
VCID (79). 
 
The described molecular changes in hypoperfused animal models occur at a time when 
microglia number increase. Microglia, resident macrophage cells in the brain, are sensitive to 
changes in the local brain environment (80). Through the release of pro-inflammatory 
cytokines/chemokines microglia could also contribute to hypoperfusion-induced white matter 
damage. In support of this, as early as 3 days after hypoperfusion inflammatory-related 
genes, such as those associated with the Jak-STAT signalling pathway and cytokine-
cytokine receptor interaction, are significantly up-regulated in white matter (46). Similarly 
activated microglia have been identified in white matter lesions in aged post-mortem human 
brain (81) with transcriptome analysis indicating alterations in genes related to the immune 
pathway (82). In the aged primate brain, microglial reactions predominate in the white matter 
and correlate with cognitive impairment (83). Notably, we have now determined that the 
number of microglial cells is significantly associated with nodal gap length and axon-glial 
disruption after hypoperfusion (84). Higher numbers of microglial cells correlate with 
decreased nodal gap length and increased paranodal axon-glial disruption, supporting the 
idea that the structural alterations observed in response to hypoperfusion could be 
secondary to a pro-inflammatory environment. With progressive myelin breakdown at 
increasing durations of hypoperfusion, phagocytosis of myelin debris may also result in 
microglial dysfunction (85) and the activation of a neuroinflammatory phenotype that 
contributes to further degenerative changes.  
 
Microvascular inflammation 
Endothelial dysfunction is considered to be one of the pivotal mechanisms of the structural 
and functional cerebral vessel alterations in SVD (10, 11) leading to VCID. Early endothelial 
failure and subsequent BBB breakdown are hypothesised to be major precipitants of 
sporadic SVD (9-11). Cerebral hypoperfusion upregulates the expression of adhesion 
molecules such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
molecule-1 (VCAM-1), markers of endothelial cell activation (68, 86). In the rat 2 vessel 
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occlusion model, markers of endothelial activation increase as early as one day post-
occlusion up to 28 days with a peak at 3 days (86). Our findings in the BCAS model, indicate 
mild hypoperfusion gradually induces upregulation of ICAM-1 and significantly at 3 months 
post operation (68). Increased expression of adhesion molecules on the endothelial surface 
functions to facilitate the attachment and extravasation of leukocytes across the BBB (87). In 
support of leukocyte activation post-hypoperfusion, an elegant in vivo 2-photon imaging 
study revealed leukocyte rolling and adhesion in the pial vessels occurs within 24 hours in 
the BCAS model (88). These changes take place in the absence of notable alterations in 
vessel structure, astrocytes or pericytes, suggesting this is an early mechanism. However 
there is no evidence that monocyte or T cells infiltrate the brain parenchyma post-
hypoperfusion (84, 89) but a detailed study of the myeloid cell population post-hypoperfusion 
is required. 
 
Opening of the blood-brain barrier and entry of blood products such as fibrinogen into the 
brain (as demonstrated in the BCAS model (48) is also likely to initiate an inflammatory 
response from resident microglia. An increase in microglial cell number following 
hypoperfusion is a consistent finding in preclinical studies (36, 37, 44-47, 49, 84) and 
activation of microglia in hypoperfused mice and rats is associated with release of matrix 
metalloproteinase, MMP2 (81), inflammatory cytokines, such as tumour necrosis factor 
(TNF)-α, interleukin (IL)-1β and IL-6, and the progression of white matter lesions (90-93). 
Increased MMPs have been consistently shown in hypoperfusion models (90-92) and 
increased expression has been shown in the white matter (91, 92) localised to microglia and 
the endothelium (91).  MMPs are proteases that degrade the extracellular matrix as well as 
tight junctions between endothelial cells and have been implicated in BBB  breakdown in 
neurodegenerative diseases (52). Furthermore increased MMPs can also degrade myelin 
(94). Increased production of reactive oxygen species by activated microglia may also drive 
endothelial dysfunction through disruption of nitric oxide signalling (95). 8-hydroxy-
deoxyganosine, a marker of oxidative stress, is increased by hypoperfusion in the 
endothelial cells in the BCAS model (64, 96). Thus a pro-inflammatory cascade is likely to 
further damage the BBB through degradation of the extracellular matrix by MMPs and 
promoting oxidative damage. 
Microvascular inflammation, as outlined previously, is a common feature of hypoperfusion 
models with markers of chronic inflammation and endothelial activation associated with 
progressive changes. It is not yet known whether inflammation is a primary driver of VCID 
and if this is triggered by intrinsic or systemic processes. Certainly from clinical observations 
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there appears to be an interplay between CNS and peripheral inflammation that contributes 
to VCID (97, 98). Additionally, age, a key risk factor for VCID, is also associated with 
alterations in microglial phenotype and function (99). There is an indication from recent 
paper (100) that white matter, glial and cognitive changes are more pronounced in older 
mice with BCAS as compared to younger mice. The mechanistic impact of advanced age 
remains to be fully explored in the different hypoperfusion models and this will be important 
to evaluate in future studies.  
 
Neuro-glio-vascular function  
As outlined above, no single cell type is likely to be solely responsible for the 
pathophysiology of VCID. Instead, disruption of the finely tuned interplay between cells of 
the neuro-glio-vascular unit (oligodendrocytes, endothelial cells, astrocytes and end-feet 
contacts, pericytes, microglia and neurons) (for review see 101) likely contributes to the 
pathophysiology. Breakdown of the neuro-glio-vascular unit disrupts the BBB, impairs the 
exchange of substances between blood and brain and alters the immune system. Critically, 
the efficient communication between the cells within the neuro-glio-vascular unit ensures 
that cerebral vessel diameter is finely tuned to neuronal activity to maintain cerebral 
perfusion and meet metabolic demands, a process known as neurovascular coupling. 
Nishino et al. (102) report that 7 days following unilateral common carotid artery stenosis, 
vascular responses to neural activity evoked by whisker stimulation are impaired. We have 
also observed impaired neurovascular coupling at 1 month following BCAS in mice (see 
Figure 4). Other studies have shown impaired vascular responses to hypercapnia (103) and 
pharmacological vasodilators (104) following hypoperfusion. In a clinical study, Sam et al. 
(105) also observed poor cerebrovascular reactivity in normally-appearing white matter that 
preceded the appearance of white matter lesions.  
 
Astrocytes contact synapses and the vasculature via end-feet processes. They are ideally 
located to mediate neurovascular coupling, facilitated by astrocytic calcium signalling and 
release of vasoactive substances from the endfoot terminus (106). Astrocytic activation has  
been detected in white matter at 7 days following BCAS surgery in mice (107) and has the 
potential to disrupt the contact between astrocytes and blood vessels. Indeed, chronic 
cerebral hypoperfusion has been shown to induce AQP4 displacement and redistribution 
after 3months BCAS (48, 68). This widespread gliovascular disruption may impair the 
regulation of blood flow, reducing the ability of the cerebral vessels to respond to dynamic 
demands in perfusion and exacerbating hypoxia. In humans, this may be further 
compounded by age-related increases in vessel stiffness and microvascular rarefaction 
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(108). However, a direct causal link between impaired neurovascular coupling and white 
matter lesion development has yet to be proven, as disrupted neurovascular coupling may 
reflect reduced tissue metabolic demand as a result of other ongoing pathological 
processes. The displacement of astrocytic endfeet or mislocalisation of AQP4 from vascular 
endfeet contacts could further impact on glymphatic clearance pathways, as has been 
elegantly demonstrated by Iliff et al. (109). As yet, the impact of hypoperfusion on glymphatic 
or perivascular drainage pathways has not been explored. Astrocytes have also been shown 
to support oligodendrogenesis through secretion of brain derived nerve growth factor 
(BDNF) in order to promote repair of white matter damage following BCAS in mice (110). 
This protective coupling between astrocytes and oligodendrocytes may also fail with age 
(111) or in neuroinflammatory conditions, and exacerbate white matter injury. Thus, the 
cellular interactions within the neuro-glio-vascular unit may be critically important for 
maintaining tissue health. 
 
Pericytes are contractile cells that ensheathe capillary endothelial cells. They have also been 
suggested to regulate blood flow in capillaries and may irreversibly constrict vessels 
following ischaemic injury (112). Although pericytes may be important regulators of BBB 
function remarkably their function in hypoperfusion models remains largely unknown. 
Perivascular macrophages have also not been studied in hypoperfusion models, but have 
been shown to mediate vascular dysfunction in hypertensive mice through production of 
reactive oxygen species (113), and may therefore be an important cell type for future study. 
Central to maintaining neuro-glio-vascular integrity is the basement membrane (BM)/ 
extracellular matrix (ECM) complex, a key interface between endothelial cells, mural cells 
and astrocytic end-feet that provides essential structural and functional stability to the neuro-
glio-vascular unit through a complex meshwork of ECM proteins (114). As has been 
indicated previously, hypoxic and inflammatory changes including the release of MMPs (90, 
91) may damage the ECM and compromise its functional integrity. Mutations in ECM-related 
proteins result in familial forms of SVD (114). It is plausible therefore that the ECM may also 
be an important target in sporadic SVD. 
 
Taken together, hypoperfusion is likely to drive key pathways related to hypoxia, 
inflammation and BBB disruption, resulting in progressive deterioration of the neuro-glio-
vascular unit (see Figure 5). The loss of integrity is likely to affect diverse functions including 
brain clearance pathways and regulation of CBF, potentially resulting in the accumulation of 
toxic waste products and ischaemic damage. Additionally, coexisting vascular risk factors 
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such as age, CAA and hypertension may exacerbate neuro-glio-vascular dysfunction and 
their impact is only starting to be explored. 
 
 
Interplay between cerebral hypoperfusion and co-morbidities 
Post-mortem studies in brains from the elderly indicate the presence of a variety of 
pathological lesions or mixed pathologies (such as white matter changes, infarcts, 
microbleeds and amyloid pathology) (115). The accumulation of these changes is likely to be 
influenced by a number of factors such as age, lifestyle and genes in addition to vascular 
risk factors. Thus in selecting appropriate animal models the study of co-morbidities should 
be considered. Surprisingly few studies have attempted to look at interactions between 
different factors. This would be important in identifying drug targets and as a basis for testing 
treatments. 
 
Of the few studies conducted, these have shown that the presence of more than one risk 
factor can exacerbate structural and functional changes in the hypoperfusion models. The 
induction of hypoperfusion in genetic or dietary models of VCI can exacerbate reductions in 
blood flow or tissue oxygen deficit, potentially through impairment of cerebrovascular 
autoregulation or modulation of tissue oxygen extraction fraction (116). Weaver et al. (116) 
demonstrated the utility of electron paramagnetic resonance oximetry to study white matter 
pO2 reductions longitudinally in a mixed SHRSP/Japanese Permissive Diet model with 
unilateral common carotid artery occlusion. In this SHRSP model, white matter lesions were 
also exacerbated in the presence of occlusion and dietary factors (116).  
 
It has been estimated that approximately 50% of AD risk is explained by traditional vascular 
risk factors (117) and most of AD cases at post-mortem have some form of vascular 
pathology (1, 118). Amyloid  protein deposition is a key hallmark of AD and believed to be 
a key driver of the pathophysiology of AD. Since rodents do not naturally accumulate A 
most studies use transgenic models that harbour mutations in the amyloid precursor protein 
associated with rare familial forms of AD (TgAPP). Critically these TgAPP mice deposit 
amyloid in the brain parenchyma and the vasculature and have provided a powerful basis 
for the study of amyloid dynamics (see summary of models on Alzforum 
(http://www.alzforum.org/research-models)). The TgAPP mouse models in combination with 
BCAS have demonstrated profound effects caused by cerebral hypoperfusion on amyloid 
dynamics and neurodegenerative changes. In the absence of other factors, blood flow 
reductions in TgAPP mice may be explained by the potent effects of soluble amyloid (Aβ) 
18 
 
on vascular function by acting as a potent vasoconstrictor (119). In another TgAPP model of 
CAA, Okamoto et al. (120) showed that blood flow reductions at 12 weeks following BCAS 
were greater in TgAPP than in wild type mice. Hypoperfusion also promoted CAA and the 
development of microinfarcts. We have similarly shown that BCAS alters the pools of 
amyloid precursor protein and amyloid peptides to promote CAA and degenerative changes 
(121). Others have similarly shown BCAS promotes amyloid deposition and exacerbates 
cognitive changes in TgAPP mice (122). CAA can also impede vascular reactivity and 
drainage pathways (123, 124) that may further increase the accumulation of amyloid β. 
Oxidative stress and in particular the superoxide-producing enzyme NADPH oxidase (NOX) 
2 plays a key role in mediating amyloid induced vascular dysfunction (125, 126). Thus, 
conceivably there may be an interplay between increased NOX and amyloid following 
hypoperfusion that exacerbates neurovascular dysfunction. Interestingly a study using the 
GCAS model has demonstrated that cerebral hypoperfusion in TgAPP mice leads to 
prominent neurovascular unit damage that appears to be cholinergically mediated, since 
galantamine treatment reduces the degenerative changes (127). 
 
A pronounced pro-inflammatory environment including activated microglia and increased 
release of inflammatory cytokines are features of hypoperfusion models. In TgAPP models 
and human AD brain a pro-inflammatory environment is closely related to the increasing 
accumulation of Aβ protein (128, 129). Studies also support an interaction between 
hypoperfusion and amyloid whereby pro-inflammatory protein levels are markedly elevated 
and cognitive impairment is greatly exaggerated (130). The interpretation of these studies 
however is somewhat limited as most TgAPP models are confounded by the overexpression 
of APP and presence of APP fragments that may themselves impact on neuroinflammation. 
Recently single App knock-in mouse (TgAPP-KI) models of AD have been developed that 
produce physiological levels of APP (131). One of these, AppNL-F/NL-F harbours the Swedish 
and Beyreuther/Iberian mutations in the APP gene to overproduce Aβ42 without 
overexpressing APP. These mice display typical Aβ pathology, neuroinflammation and 
memory impairment in an age-dependent manner (131). Collectively, these observations 
suggest a vicious cycle whereby vascular factors (of which hypoperfusion is a common 
mechanism) promote the accumulation and/or impedes clearance of amyloid leading to 
impaired vascular reactivity, promotion of hypoperfusion, oxidative stress, microvascular 
inflammation and further production of amyloid (Figure 5). 
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Pre-clinical investigation of drug targets  
Assessment of pipeline drugs can be evaluated in preclinical models before clinical trials are 
initiated providing a translational opportunity. However, in reality there has been a major 
translational block with few agents showing promise in human VCID (see suggestions below 
for ways to overcome this). We provide examples that currently appear to be of potential 
value. One compound that has shown promise is cilostazol, a potent phosphodiesterase III 
inhibitor, which has been widely used as an antiplatelet agent for the prevention and 
treatment of peripheral arterial disease. Cilostazol normally does not cross the BBB but 
increases cyclic AMP in vascular cells and can exert multiple beneficial effects on the 
vasculature such as endothelial protection (132, 133), maintenance of microvascular 
integrity (134), vasodilatory, anti-oxidant, anti-inflammatory effects and regulation of smooth 
muscle cells (135). Moreover, in vitro experiments showed that cilostazol promoted 
differentiation of oligodendrocyte precursor cells (OPCs) (110). In the BCAS model, pre-
treatment and post-treatment of cilostazol reduced endothelial activation, suppressed 
microglial proliferation and improved cognitive function without affecting resting CBF and 
white matter integrity (68). After three months of hypoperfusion, BBB structure is preserved, 
suggesting cilostazol restored gliovascular disruption via endothelial protection without 
affecting white matter directly (68). These reports suggest that cilostazol has beneficial 
effects on the gradual progression of VCID, particularly in the early stages. In the rat 2 
vessel occlusion model, administration of cilostazol showed a remarkable protection against 
hypoperfusion-induced white matter damage including demyelination leading to 
improvement of cognitive impairment. In the 2 vessel occlusion model, cilostazol appears to 
afford greater effects potentially by crossing the disrupted BBB and directly affecting the 
white matter (64, 136). In experimental studies relevant to AD, cilostazol may protect against 
amyloid induced cognitive deficits and oxidative damage (137). Cilostazol has also been 
shown to reduce vascular amyloid by drainage mechanisms that promote clearance (138).    
In a pilot study of patients with moderate AD (139) and in a larger retrospective study of 
patients with mild dementia (140), receiving donepezil, cilostazol add-on treatment 
demonstrated significantly increased cognitive scores in comparison to baseline.  
 
Minocycline is another compound that has shown preclinical utility in several models relevant 
to VCID. Minocycline is a semi-synthetic tetracycline with FDA-approval for the treatment of 
acne vulgaris. It is highly lipophilic and readily able to cross the BBB. The drug is shown to 
be a potent inhibitor of inflammatory responses in a number of vascular conditions where 
microglia are activated, including hypertension (141), stroke (141, 142) and cerebral 
hypoperfusion (84, 143, 144). In particular, administration of minocycline for 3 months in the 
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BCAS model restored the hypoperfusion-induced impairment in white matter function related 
to a reduction in the number of microglia (84). Other studies, in which white matter is 
damaged by cerebral hypoperfusion via unilateral occlusion (143), two vessel occlusion 
(144) and in hypertensive stroke prone rats with two vessel occlusion (141) have also 
convincingly shown protective effects of minocycline. Minocycline has also been shown in 
animal models of cerebral amyloidosis to improve cognition (145) via inflammatory/oxidative 
stress mechanisms (145, 146) independently of amyloid levels. Interestingly, additional 
beneficial effects of minocycline include reduction in gelatinase activity and in spontaneous 
haemorrhage (146, 147). These observations suggest minocycline may be a promising 
candidate for use in VCID, whilst it is currently already being trialled for mild AD (see 
http://www.kcl.ac.uk/ioppn/depts/oldage/research/Medication-studies/Clinical-
Trials/minocycline-in-alzheimers-disease-(MADE).aspx). 
 
As indicated above increased MMPs are closely related to the pathophysiology of white 
matter damage and have also been shown to be increased in human VCID (148).  Genetic 
deletion of MMP2 is protective against the effects of BCAS in the mouse model (90). In a rat 
model, of two vessel occlusion, inhibition of MMP2 protects against hypoperfusion white 
matter damage and reduces the extent of glial activation (90). A broad spectrum MMP 
inhibitor was also shown to protect against BBB opening in the mouse BCAS model and 
against the ensuing white matter pathology and cognitive deficits (52). MMP inhibitors, whilst 
potentially protective in pre-clinical models of hypoperfusion, their use needs to be carefully 
considered in human VCID where MMP effects are likely to be complex and involved in both 
the contribution to the damage but also in the repair processes (see 149 for review). 
 
Life-style factors, including environmental enrichment and physical activity have been 
proposed as strategies to alleviate cognitive impairment in VCID. A recent report by our 
groups showed beneficial effects of environmental enrichment in a mouse model of chronic 
cerebral hypoperfusion by BCAS particularly in the white matter (49) that attenuated working 
memory deficits (150). These effects included a dramatic reduction in astrocyte damage and 
activation and microgliosis (49). It was found that limited rather than full-time exposure to 
environmental enrichment was more beneficial. Therefore, the implementation of even 
limited environmental enrichment may be beneficial for patients diagnosed with VCID.  
 
Collectively the experimental studies provide pre-clinical support for drug and lifestyle 
modification which may hold potential clinical value in SVD and VCID. Although further 
experimental studies are needed, moderate environmental enrichment appears a safe and 
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effective future interventional strategy for cerebrovascular diseases, especially for patients 
with VCID. 
 
Important considerations of the models; How can we close the gap between rodent 
models of chronic cerebral hypoperfusion  and human VCID? 
In order to effectively translate information generated from animal models such as cerebral 
hypoperfusion, we need to consider the general design, methodology and reporting of 
preclinical animal studies. Since the basis of the models are dependent on the extent of 
reduction of cerebral perfusion, it would be critical to monitor blood flow in each study. MRI 
with arterial spin labelling or similarly sensitive methods would be ideal to assess regional 
alterations in blood flow, particularly in subcortical areas. It is also important to recognise 
that blood flow is mostly measured in anaesthetised animals and may differ from that 
obtained in awake animals, particularly when vasodilatory anaesthetics such as isofluorane 
are used. Additionally, monitoring blood flow alterations in the white matter would be 
important. This measure is seldom reported in rodent models or in VCID, presumably 
relating to technical challenges regarding access and the inherently low blood flow in white 
matter, where small changes in flow may be difficult to detect reliably.  
 
The outcome measures in preclinical models, including those relating to extent of white 
matter damage, may be influenced by operator differences, background strain of the mice 
(cerebrovascular differences), size of constrictor devices, anaesthesia, time of application of 
coils and environment (pathogen status, temperature). In some studies animals are allowed 
to recover between the placement of the first and second coils to allow restoration of 
cerebral haemodynamics (40, 44, 46-48). Furthermore, the use of markers to assess white 
matter pathology can also vary. For example histological approaches such as Luxol fast blue 
and histology, whilst useful for detection of overt white matter lesions are not sufficiently 
sensitive to detect diffuse white matter changes. Instead, immunohistochemical approaches 
are required and one of the most sensitive markers of damage is myelin associated 
glycoprotein which is now used for detection of hypoxia-induced white matter pathology in 
human brain (18). Arguably, a further refinement would be to conduct ultrastructural analysis 
of white matter to assess myelin and axonal alterations, albeit these approaches are 
challenging within the corpus callosum. In addition to pathological changes induced by 
reduced blood flow itself, it is important to recognise that induction of hypoperfusion in 
animal models may result in alterations to the vasculature, independent of perfusion deficits 
that could also be detrimental. For example, application of microcoils or ligation of vessels 
may alter autoregulation, vascular stiffness or pulsatility and impact on the dynamics of 
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cerebrospinal fluid circulation.  Each of these mechanisms are proposed to contribute to  
VCID (9) and thus it would also be of interest to determine whether they are altered in the 
hypoperfusion models. It also needs to be considered that localised cellular inflammation 
may also be increased in the tissue surrounding the microcoils or constrictor devices and 
contribute to the pathological and behavioural outcomes (48). Critically age is a major risk 
factor for development of VCID and yet most studies continue to use relatively young 
rodents in which endogenous repair mechanisms will be more efficient. In older animals, 
white matter lesions are indicated to be more pronounced (100) and it may be predicted that 
these would be less amenable to intervention. Age and additional co-morbidities (such as 
systemic inflammation) need to be carefully factored in to preclinical testing of future drug 
targets if we are to enable meaningful translation from models to the clinic. 
 
 
In summary, it must be recognised that there are no animal models which perfectly 
recapitulate all of the features of VCID. However, several rodent models reflect aspects of 
human VCID and are pertinent to tease out specific questions that are impossible to readily 
address in human studies. To close the gap between rodent models and human VCID, it is 
therefore important to understand the pathological and cognitive features of preclinical 
models in order to select the appropriate model for the purpose.  
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Figure legends: 
Figure 1 
Multiple experimental models have been developed in order to study disruption of cerebral 
blood flow. Focal ischaemia models, largely developed to study stroke pathophysiology, can 
be achieved through targeted occlusion of a specific vessel, leading to reductions in flow 
(>70%) that are spatially restricted to the vessel’s territory. Alternatively, intra-arterial 
injection of emboli leads to multiple infarcts. In one model, SHRSP, strokes develop 
spontaneously. Global ischaemia models recapitulate severe (>90%) blood flow reductions 
to the forebrain. Due to the severe reductions in flow typically observed in models of 
ischaemia and resultant ischaemic neuronal damage, new models have since been 
developed and refined in order to mimic the subtle yet chronic reductions in blood flow 
relevant to vascular cognitive impairment. Stenosis or occlusion (rats only) of the common 
carotid arteries induces moderate blood flow reductions (~30-50%) without acute ischaemic 
damage. Abbreviations: BCAS, bilateral common carotid artery stenosis; SHRSP, 
spontaneously hypertensive stroke prone rat 
 
Figure 2 
Adapted from Hattori et al. J Am Heart Assoc. 2016:5(2). A. Temporal profile of cortical 
surface CBF  in mice subjected to gradual occlusion of both common carotid arteries 
(GCAS) (n=12) and bilateral common carotid  stenosis with microcoils (bilateral common 
carotid  stenosis (BCAS); n=7). The levels of cortical surface cerebral blood flow  (CBF) 
estimates at indicated time points (before, and 1, 3, 7, 14, and 28 days after each surgery) 
are shown as percentage of the baseline CBF. Two groups were not significantly different in 
2‐way repeated‐measures ANOVA. *P<0.01, GCAS vs BCAS at indicated each time point. 
B. Regions of interest (ROIs) used for measurement of CBF images obtained from arterial 
spin labelling magnetic resonance perfusion imaging. The CBF values in cerebral cortical 
area were calculated from the 6 circular ROIs in blue and those in the subcortical area from 
the 2 circular ROIs in red.  C. Representative multislice coronal CBF images obtained from 
arterial spin labelling at the Bregma and hippocampal levels pre‐GCAS surgery and at 14 
and 28 days after GCAS surgery.  
 
Figure 3 
A. Fibre-optic oxygen sensors  were implanted stereotactically into the corpus callosum of 
anaesthetised sham and hypoperfused mice (n=6/gp) at different times post-surgery. The 
measurement of tissue oxygen tension (pO2) provides a measure of oxygen availability at 
the cellular level. B.  At all times post-hypoperfusion, pO2 levels were significantly reduced 
to hypoxic levels (<10mmHg) ****p<0.0001 
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Figure 4 
Laser speckle imaging was used to assess vascular responses to whisker stimulation in 
anaesthetised sham (n=7) and hypoperfused mice (n=5). (A) Neurovascular coupling was 
significantly impaired in hypoperfused mice compared to sham, *p<0.05. (B) Representative 
responses to whisker stimulation from sham and hypoperfused mice. The onset and end of 
whisker stimulation are highlighted by arrows. 
 
Figure 5 
Summary of proposed pathways by which chronic cerebral hypoperfusion may lead to 
cognitive impairment.  Cerebral hypoperfusion reduces tissue oxygen levels (pO2) leading to 
oxidative stress and endothelial injury. The ensuing microvascular inflammation (ECM 
disruption, increased MMPs and ROS; inflammatory cytokines) is associated with activated 
microglia and astrocytes resulting in disruption of axon-glial integrity and neurovascular 
coupling.  These inter-related pathways may lead to cognitive impairment. Cerebral 
hypoperfusion can also increase amyloid which may potentiate these mechanisms and  
promote further degenerative changes and cognitive impairment. Abbreviations: ECM, 
extracellular matrix; MMP, matrix metalloproteinase; ROS, reactive oxygen species; BBB, 
blood brain barrier 
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